Canntab Therapeutics Ltd (CTABF)

[Pisd]

Canntab Announces Corporate Update

6:30 am ET November 22, 2022

TORONTO, ON / ACCESSWIRE / November 22, 2022 / Canntab Therapeutics Limited (CSE:PILL)(OTCQB:CTABF)(FRA:TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing an update on several matters impacting the Company.

Over the past number of months, Canntab has undertaken a strategic review of its domestic operations in the context of the global market. The Company's conclusion, which was first communicated in the Company's MD&A for the year ended May 31, 2022 filed under its SEDAR profile on September 28, 2022, was that in the absence of a complete pivot away from our core competencies into a crowded consumer market for pre-rolls and vaporizer devices, focusing exclusively on tablet manufacturing for the domestic market is not financially viable and the Company was repositioning its production capabilities to a small batch special order basis and management was focusing its business development efforts to establish licensing partners in non-Canadian markets to exploit the valuable patents held by the Company.

On November 17, 2022, Canntab received a notice from its landlord indicating that the lease for Canntab's Markham manufacturing site will not be extended. The lease expires on December 31, 2022. Despite the Company's long tenure at the Markham location, the landlord has declined to extend Canntab's lease. Canntab has contacted Health Canada to engage in discussions to determine how Canntab may retain its various Cannabis licenses held by the Company.

Mr. Goldstein, Co-Founder, CFO, and interim CEO of the Company stated, "Canntab has already begun the process of contacting several other Canadian license holders with the intent of moving approximately $600,000 of Cannabis inventory to other licensed facilities made up primarily of finished bottled products, bulk tablets, and some cannabis distillate. Canntab expects to realize ongoing revenues from this asset."

Canntab will also immediately seek to move its production, testing and manufacturing equipment to establish its tablet manufacturing process at another licensed facility in Canada or elsewhere.

The Company as previously stated in its annual report and recent MD&A discussions, had already been pursuing a new strategy of focussing on international licensing arrangements coupled with a royalty regime based on its proprietary and patented technologies.

Canntab received its 4th issued patent and 2nd in Australia on October 6, 2022, entitled "Modified release multi-layer cannabinoid formulations". Canntab anticipates receiving a similar patent approval sometime in 2023 in both the USA and Canada. Canntab's intention is to license its proprietary technologies to other parties that will manufacture our tablet formulations in their respective jurisdictions. Canntab intends to transfer the technology and know-how to each licensed entity and discussions spanning several months are well underway with arm's length third parties in Europe, Scandinavia, Africa, Australia, South America and the United States.

In addition, Canntab is speaking with privately owned cannabis companies who are looking to secure liquidity through the public markets or otherwise grow their businesses in a merger transaction.

Mr. Goldstein added, "We will no longer need to spend the money necessary to maintain Canntab's licensing status at the Markham facility which has not proven to be profitable. We can now operate in a very low overhead environment and focus on licensing and monetizing our intellectual property."

About Canntab Therapeutics Limited

Canntab is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Long referred to as Cannabis 3.0 by the Company, Canntab's proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world. These include once a day and extended-release formulations, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes License and a Cannabis Research License.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

For more information, please contact:

Canntab Therapeutics Limited

Richard Goldstein

Chief Financial Officer &

Interim Chief Executive Officer

[phone]

[e-mail]

[Pisd]

Holding tiny position here..valuable patents??.. waiting on news.. CTABF$...

[BesaoT35]

Can the board administrator add the relevant news items to the news section for CTABF? We are not getting news flow for this stock.

[BesaoT35]

There is no PXLIF IHUB functional message board. I will post my question here for that reason. Can an american buy PXLIF on the Israeli stock market? Is that what you did Milo?

[MjMilo]

THis is reality..the future....

https://www.jpost.com/health-science/israeli-medical-cannabis-company-selected-for-exclusive-french-pilot-657204

https://www.jpost.com/health-science/israeli-medical-cannabis-approved-for-export-to-germany-france-651867

Note the dosage levels...none of this 3 mgm bs.

The Canadian government needs to get its' shit together.

[MjMilo]

NO clue why nobody is making a market for Panaxia stock in N. America.

I am unimpressed with Canntab.

I wish you luck on your investment here.

Maybe at some point they will be interested in their shareholders and the share price...

Right Mr. Goldstein?

[MjMilo]

I suppose they could but that is not their business plan right now.

[BesaoT35]

News Today. Canntab Therapeutics has been issued a second patent for immediate release cannabinol tablet. See news at OTC website.

[BesaoT35]

OTCBB for PXLIF. Price is $0.832. Warning: Only Unsolicited Quotes. There is no bid and no ask. What to make of this?

[BesaoT35]

Thanks MJM. PXLIF is the ticker symbol. There seems to be an existing equity for Panaxia but the price is listed as zero and there is no trading volume.

I will go to the OTC website

Perhaps this is a new listing.

Couldn’t CTABF strengthen the dosage of tablets for sale outside of Canada?

[MjMilo]

If you want to look at a company that has it's shit together..look at Panaxia.

Pills of all dosages....different technologies to deliver medicine...clinical trials...all in Israel.

https://panaxia.co.il/portfolio/

This company, Cantab has little to no hope of being successful despite who sits on their BOD because of the Government of Canada's bungling of Cannabis legalization.

Capping the amount of medicine that can be put in a regulated pill is bs..where Cannabis is concerned.

A few milligrams of THC does nothing.

A joke.

[MjMilo]

I walked away from this company after close contact with the CFO..We were in direct talks about a number of other things and it became quite apparent that Mr. Goldstein had no interest in his shareholders nor the share price based on the way he spoke to us.....and despite his interest in some business opportunities we presented to him he continued to get even more brash and bullying.....showed himself to be a boorish self interested man only intent on seeing what he could get for himself....never had any interest in working with us and our team and would not adhere to anything confidential so we could continue our discussions.....

So we walked..and I then walked from this turd of a company...I sold all my holdings.

One has to realistically ask why the stock doesn't trade any volume..why it never moves...and why the company doesn't care.

Not something I want to be invested in...

And by the way...because of Canadian regulatory rules around Cannabis..the company is limited into how much medicine they can put in one pill.

The government here in Canada has gone out of it's way to hamper both consumers and manufacturers.

I have zero interest as do thousand of people in this country in buying my cannabis from licensed entities.
The potency is low and the prices are disgusting.

The government had promised an end to the black market.

It is thriving and stronger than ever...and delivering quality product for a good price.

[BesaoT35]

Canntab Therapeutics begins delivery on a $1.3 million (Canadian) order to Medipharm Labs Corp. This might be why the stock price is up a bit in the past few days. Larry Latowsky (CEO) says that 2 SKUs of a total of 5 SKUs are already shipping. The products are pressed tablets and caplets. Terpenes are a listed and measured ingredient along with the standard THC and CBD. These terpenes might be a unique and differentiating aspect to Canntab products.

The news is listed on the OTC website Dec 1, 2020

[MjMilo]

Why don't you ask the company? Contact Richard Goldstein..the cfo.

[BesaoT35]

Did the Florida operations ever get up and running? What about Canadian tablet manufacture? Any patent office news? Thanks.

[MjMilo]

It's a very confusing company to figure out..One would think with everything they have going on there'd be activity...but this one is dead....I don't like it at all.

[BesaoT35]

Not a lot of chatter here for CTABF. Is there any future catalyst coming up? If Dems federally reschedule cannabis what would that mean for CTABF?

[MjMilo]

Canntab receives the first of 13 patents applied for.


https://canntab.ca/press/

[BesaoT35]

The market cap of CTABF is $17 million. Nobody trades this company. OWCP has a market cap of $4 million but gets over one hundred trades in a single day.

I mentioned OWCP before here and got ridiculed for the mention. Milo are you now positive on OWCP? Are you still positive on CannTab?

Do you trust the management for CTABF?

[MjMilo]

https://canntab.ca/press/

[MjMilo]

https://worldclassextractions.com/2020/07/29/world-class-extractions-acquires-11500000-face-value-hydrx-farms-ltd-debenture/


Mr. Goldstein is the CFO and one of the founders of Canntab.

[MjMilo]

This company is associated with World Class Extractions...a publicly traded company.....DD the recent news.

[MjMilo]

NO.

[BesaoT35]

If a shareholder bought shares on the OTC in the USA could those shares be sold on the Canadian exchange? Perhaps a higher volume north of the border makes for more efficient trading in Canada.

[MjMilo]

Just wish the world knew about this gem of a company....

The volume is very low...that concerns me....but so is the share structure.

Waiting for more details on the signed 1 million dollar deal with Medipharm and other possible deals.

Soon...lol

[MjMilo]

THis is very big news for the company...first confirmed order for 1 millions dollars....

The market will take notice sooner than later...look at the chart.....climbing since late March on low volume.

[MjMilo]

Canntab Therapeutics
For Immediate Release
2020_06_02

CANNTAB AND MEDIPHARM LABS ENTER INTO A WHOLESALE TABLET PURCHASE AGREEMENT


TORONTO, June 2nd, 2020/ – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it is today beginning production of its instant release tablets and has already entered into its first purchase agreement with MediPharm Labs (“MediPharm”) (TSX:LABS)(OTCQX: MEDIF)(Deutsche Borse: MLZ), a global leader in pharma quality cannabinoid based products.

Canntab received its first order under the agreement today, and the value of the full agreement will exceed $1 million. Orders under the agreement will be composed of a mix of Canntab’s proprietary instant release tablets delivering THC, CBD and a combination of THC/CBD in 12 different strengths. MediPharm will purchase and distribute cannabis products on a non-exclusive basis across Canada, through licensed provincial dispensaries.

The exact value of shipments under the agreement will be determined no later than June 30, 2020 and will depend on the final concentrations of Canntab’s instant release tablets chosen by MediPharm.

Canntab has already filed its 60 day notice for approval to sell this line of products with Health Canada and expects that its tablets will be available for sale in the early summer. Canntab is currently the only company in Canada capable of delivering THC, CBD and/or any combination THC/CBD in pharmaceutical grade tablets or hard pills.

Jeff Renwick, CEO of Canntab said “we are very excited and pleased to have achieved this major milestone in our short history as a company. We are especially pleased to have accomplished this major milestone in the face of the Covid-19 Pandemic which has caused major uncertainty and disruption in world markets, including, Canada. Canntab has continued to work diligently to build shareholder value during this crisis as we are designated an essential business. Signing our first purchase order with a quality partner having a global reach such as MediPharm is simply the tip of the iceberg for Canntab.”.

“We’re pleased to be working with Canntab who are leading the way in manufacturing innovative cannabis based tablets,” said Pat McCutcheon, Chief Executive Officer, MediPharm. “With MediPharm’s robust supply chain and established distribution channels, we are excited to roll out novel high quality tablet products in the coming months to medical and adult-use consumers across Canada.”

Canntab has filed 13 patents in Canada and United States that cover a range of processes and formulations that it uses to create its precision oral delivery hard tablets, the future of medical cannabis. These patents include Canntab's proprietary nano-emulsification technology, granulation process, methods of manufacturing, and covers its full line of precision oral delivery hard tablets including; Instant (Immediate) Release Tablets, Extended Release Tablets, Oral Dissolvable Tablets and Bi-Layered (Modified Release) Tablets. Canntab has also filed a patent for an exclusive formulation of THC and CBD for the treatment of opioid addiction treatment therapy.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability. The future of medical cannabinoid solutions.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Additionally, Canntab through its wholly owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in Florida, USA.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

For further information:
Canntab Therapeutics Limited
Jeffrey Renwick
Chief Executive Officer
[phone]
[e-mail]

Richard Goldstein
Chief Financial Officer
[phone]
[e-mail]

[BesaoT35]

152 shares traded in the US and we are up 10%. I am not complaining, but doesn’t it seem odd or unusual that such small trading volumes result in such sizable percentage changes in price. If I were to buy a thousand shares perhaps the price would rise 30%.

[MjMilo]

[MjMilo]

Canntab Therapeutics
For Immediate Release
2020_05_15

Canntab Appoints Joshi Laxminarayan as Chief Scientific Officer



TORONTO, May 15th, 2020/ – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the appointment of Joshi Laxminarayan as Chief Scientific Officer (CSO). In his role as CSO, Mr. Laxminarayan will be responsible for directing Canntab’s strategic research and partnership program, and overseeing the Company’s ongoing manufacturing and distribution operations.

Mr. Laxminarayan is a pharmaceutical scientist with a successful history of bringing to market a number of pharmaceutical drugs throughout a career spanning over 25 years. Mr. Laxminarayan began his career in India, as a bench chemist, and most recently acted in a consultant role to the Company, as Director of Quality Assurance & Quality Control, where he assisted with the research and development needed to formulate the Company’s current product line. His expertise in nano emulsion, extended release, and poorly soluble drug development, has played a crucial role in the Company’s research and development with respect to cannabis oil inputs.

“Joshi has played an integral part in helping Canntab strengthen its competitive position and relevance, and distinguish itself in the pharmaceutical industry. His appointment as CSO is expected to evolve as we continue manufacturing, into a position where he can oversee not only our ongoing Research & Development, but also our day to day manufacturing and distribution operations,” explains Jeff Renwick, Co-founder and CEO of Canntab. Mr. Renwick continues, “As Canntab enters the next phase of its growth, Mr. Laxminarayan will be invaluable to our continued success, driving us closer to our goal of being the world leader in solid oral dose therapeutic cannabis solutions.”



About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Additionally, Canntab through its wholly owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in Florida, USA.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

For further information:
Canntab Therapeutics Limited
Jeffrey Renwick
Chief Executive Officer
[phone]
[e-mail]

Richard Goldstein
Chief Financial Officer
[phone]
[e-mail]

[MjMilo]

6 Month Charts CANNTAB


chart Canadian side

chart US side

[MjMilo]

IT's starting to get proper valuation in line with their activity...If you watched the webinar you'd know they are already in the manufacturing process..I expect them to announce a major distribution deal with some pharmacy chains in Canada very soon..Also they are working with other countries..they mentioned Australia and Mexico.

They are now keeping the proper valuation between the two sides very close as they should do..Once this stock hits the radar it will start trading more actively especially on the US side..They only have 32 million shares outstanding.

People should be getting in now on the US side before this wakes up!

It will be happening soon as sales start in Q3 as per Larry Latowsky, chairman of Canntab.

[MjMilo]

Webcast

http://wsw.com/webcast/canaccord39/ctabf/

[MjMilo]

https://ca.finance.yahoo.com/news/canntab-present-canaccord-genuity-2020-113000524.html


The webcast of the Company's presentation will be available at: http://wsw.com/webcast/canaccord39/ctabf/


TUESDAY MAY 12/2020 @ 9:20am EST

[MjMilo]

Not until they have the approval from Health Canada and that is in the works.

[BesaoT35]

Usually a move of 43% would show up on investors’ stock screens and then generate some curious its or interest. Not so here. It would be nice to have more of a following here. Can orders be placed for any products yet?

[MjMilo]

Nothing traded on the CDN side so far...

[BesaoT35]

400 shares traded and up 43%. I suppose there are more shares traded in Canada. I am surprised very few traders have an interest here.

[MjMilo]

Starting to move up in anticipation of approval from Health Canada and production this summer! (PILL on the Canadian side)

[MjMilo]

The company is under the radar for some reason. Spend some time on their website and read.
I have repeatedly tried to become a moderator here but with no luck so I can expand this message board and provide updated info.

I trade the stock on the CDN side as PIll..you are correct.

I also have a senior contact within the company but am not privy to anything "inside".

Before Corona hit I was invited to the company headquarters north of Toronto.
Obviously that has been put on hold.

Strong IP portfolio with 13 patents pending and a positive finding of patentability from the
International Preliminary Report on Patentability.

https://canntab.ca/wp-content/uploads/2020/04/Canntab-Therapeutics-Product-List-April-2020.pdf

https://canntab.ca/wp-content/uploads/2020/04/Canntab-Therapeutics-Corporate-Presentation-April-2020.pdf


They currently have a small crew working on their several different pill versions which must be submitted to Health Canada for approval. Once approved and it shouldn't be that much longer sales of both THC and CBD based tablets can begin in Canada.

Their operation in FLorida which is scaling up will produce and supply CBD based pills only for the time being for distribution across the country where allowed.

[BesaoT35]

On the Canadian exchange this stock trades as PILL I think. Is there another investor board where the company is discussed in either English or French? A tablet is an important development. Why is nobody interested? Is there competition that I am not aware about?

[MjMilo]

OWC?...don't make me laugh.

[BesaoT35]

There is also a Florida facility for CBD tablets. No THC in Florida I believe. Manufacturing a pharmaceutical might be considered to be an essential activity in a Covid -19 restricted economy. Maintaining social distancing might be a doable thing to accomplish in a manufacturing setting.

How many employees does Canntab currently have? Are they hiring a sales force?

What sort of intellectual property does CTABF have that would stop a competitor from copying their cannabinoid tablets? The patents I understand are pending and not yet granted.

Precise medical dosing has to be a widely sought after product that health care providers could confidently recommend or prescribe? OWCP has a tablet. Who else is tablet competition? GWPC might be a buyer for a medical grade tablet.

What is the current status of the 5 or so patents that are pending? Is the company viable if the patents are denied?

[MjMilo]

Most employees are now working from home and not at the Markham facility north of Toronto...

There is a skeleton staff working at the plant producing tablets to be sent to Health Canada for final approval...

Once that happens...sales can begin...

Sales will start later this summer.

[MjMilo]

Just read the pr's and filings....they have been awarded all licenses to now produce and sell in Canada...

Currently setting up operation in FLorida to sell tablets(cbd) into US market.

This one is still very much under the radar but no-one has what these guys have...

Not for much longer.

[BesaoT35]

What and when might the next catalyst event occur for CTABF. Would it be manufacturing news? or distribution news? Or sales news? Or patent approval? Or pharmacokinetic study results? Anybody have any intuition or knowledge in this area of medical cannabis?

With OWCP suspending it’s tablet program that leaves CTABF in the medical dosing arena much or any known competition. CVSI might have an interest in this area of medical cannabis. What other competitors want a tablet? GW Pharmaceuticals is another obvious suspect.

Thanks in advance for any helpful insight here.

[MjMilo]

At some point in the near to immediate future,..the market will take notice of what is happening in Markham Ontario...

Canntab!

[JackAskSlap]

Buy time coming

[MjMilo]

CANNTAB CLOSES FINAL TRANCHE OF PRIVATE PLACEMENT FOR AGGREGATE PROCEEDS OF $3.7M

TORONTO, March 16th, 2020 – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has closed the final tranche of its previously announced non-brokered private placement (the “Private Placement“) by issuing 1,291,000 units (“Units“) at a price of $0.50 per Unit for gross proceeds of $645,500. Together with the funds raised under the first tranche of the Private Placement, the Company has received total gross proceeds of $3,725,500 under the Private Placement.

“With the gross proceeds from this financing we now have the capital to completely implement our business plan. “Raising significant equity during these extraordinary market conditions coupled with the inherent recent challenges in the Cannabis space in particular is a testament to the level of interest which exists in the future of Canntab”” explains Richard Goldstein, Co-founder & Chief Financial Officer of Canntab. Mr. Goldstein concludes, “we began as a pharmaceutical company more than a decade ago, and we will continue to operate as a pharmaceutical company producing the most advanced medical cannabis solutions.”

Closing the Final Tranche

The Private Placement was previously announced on February 6, 2020. Pursuant to the closing of both tranches of the Private Placement, Canntab has issued 7,451,000 Units for gross proceeds of $3,725,500. Each Unit consists of one common share (a “Common Share”) and one full warrant (a “Warrant”) to acquire an additional common share at a price of $0.75 per share for a period of 24 months.

In connection with the Private Placement, the Company paid fees to a syndicate of registrants that were comprised of cash fees of $228,095 and issued 456,190 finder’s warrants, which each entitle the holder thereof to purchase one Common Share at a price of $0.50 for a period of 24 months.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Additionally, Canntab through its wholly owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in Florida, USA.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

For further information:

Canntab Therapeutics Limited

Jeffrey Renwick

Chief Executive Officer

[phone]

[e-mail]

[MjMilo]

From the front page of the Canntab website:

WE ARE CANNTAB THERAPEUTICS

We just received our Cannabis Processing and Medical Sales Licence from Health Canada!

Stay tuned for more big news in the coming weeks as we ramp up into full production!